Due to the structural similarity of BTK, EGFR and bone marrow X kinase (BMX), ibrutinib could potently inhibit BMX and EGFR in NSCLC cells, but only those with an EGFR‐mutant (Ahn et al., 2017; He et al., 2017; Molina‐Cerrillo et al., 2017; Wang et al., 2016; Wu et al., 2015). Here, BTK is linked to non-small cell lung carcinoma.